New Insights of Phospholipase A2 Associated Neurodegeneration Phenotype Based on the Long-Term Follow-Up of a Large Hungarian Family

Renata Toth-Bencsik¹, Peter Balicza¹, Edina Timea Varga², Andras Lengyel¹, Gabor Rudas³, Aniko Gal¹ and Maria Judit Molnar⁺*

¹Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary, ²Department of Neurology, Albert Szent-Györgyi Medical and Pharmaceutical Center, University of Szeged, Szeged, Hungary, ³MR Research Center, Semmelweis University, Budapest, Hungary

Introduction: Phospholipase A2-associated Neurodegeneration (PLAN) is a group of neurodegenerative diseases associated with the alterations of PLA2G6. Some phenotype-genotype association are well known but there is no clear explanation why some cases can be classified into distinct subgroups, while others follow a continuous clinical spectrum.

Methods: Long-term neurological, and psychiatric follow-up, neuropathological, radiological, and genetic examinations, were performed in three affected girls and their family.

Results: Two 24-years old twins and their 22-years old sister harbored the p.P622S, and p.R600W mutation in PLA2G6. The age of onset and the most prominent presenting symptoms (gaze palsy, ataxia, dystonia, psychomotor regression indicated atypical neuroaxonal dystrophy (ANAD), however, optic atrophy, severe tetraparesis would fit into infantile neuroaxonal dystrophy (INAD). All siblings had hyperintensity in the globi pallidi and substantiae nigrae which is reported in ANAD, whereas it is considered a later neuroradiological marker in INAD. The slow progression, rigidity, bradykinesis, and the prominent psychiatric symptoms indicate PLA2G6-related dystonia-parkinsonism. Abnormal mitochondria, lipid accumulation and axonal spheroids were observed in the muscle and nerve tissue. Brain deposition appeared 6 years following the initial cerebellar atrophy. Mild MRI alterations were detected in the asymptomatic carrier parents.

Conclusion: The colorful clinical symptoms, the slightly discordant phenotype, and the neuroimaging data in the family supports the view that despite the distinct definition of...
INTRODUCTION

Phospholipase A2-associated Neurodegeneration (PLAN) (OMIM: 610217) is a group of neurodegenerative diseases that are associated with the alterations of the PLA2G6 gene, resulting in pathological brain iron deposition (NBIA). PLAN is divided into four subgroups based on the phenotypes, age of onset and rate of progression: (1) classical infantile neuroaxonal dystrophy (INAD), (2) atypical neuroaxonal dystrophy (ANAD), (3) PLA2G6-related dystonia-parkinsonism (DP), and (4) autosomal recessive early onset parkinsonism (AREP) (Guo et al., 2018).

The PLA2G6 deficiency results in cerebellar atrophy and iron deposition in the basal ganglia and optic nerves (Carrilho et al., 2008). The neuropathological hallmark of the disease beside the iron accumulation, are the presence of neuroaxonal spheroids, abnormal \( \alpha \)-synuclein proteins, hyperphosphorylated tau proteins, in some cases Lewy bodies (LBs), neurofibrillary tangles and neuropil threads (Guo et al., 2018).

The age of onset and the clinical manifestations are the main criteria used to make distinctions between the different subtypes of PLAN (Kurian et al., 2008); however, a broad and overlapping presentation of clinical phenotypes exist among the different subgroups (Ji et al., 2019). There are only a handful of publications with long-term longitudinal retrospective study designs, which help us to understand the transition from one subgroup to the other. Here, we present the long-term clinical retrospective study, the neuropathological and genetic features of a large family having one previously unreported and one known pathogenic compound heterozygous rare variants of the PLA2G6 gene.

MATERIALS AND METHODS

Molecular Genetic Analysis of the PLA2G6 Gene

DNA samples were extracted from blood by the QIAamp DNA blood kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. The total coding region of PLA2G6 gene was genotyped with Sanger sequencing using both forward and reverse primers according to ABI Prism 3500 DNA Sequencer (Applied Biosystems, Foster City, United States). The sequences were aligned with the human reference genome (ENST00000332509.7, NM_003560) using BLAST application.

Multiplex Ligation-Dependent Probe Amplification

To identify exonic deletions and duplications within the PLA2G6 of patients, multiplex ligation-dependent probe amplification (MLPA) was performed by the SALSA MLPA P120 PANK2/PLA2G6 (MRC Holland, Amsterdam, Netherlands), according to the manufacturer’s instructions. MLPA peak plots were assessed using COFFALYSER Software version (MRC Holland, Amsterdam, Netherlands).

In silico Analysis

Mutation interpretation analysis was conducted using Alamut 2.0 (Interactive Biosoftware, San Diego, CA, United States). The significance of identified alterations was screened with HGMD\(^2\), dbSNP\(^3\), and ClinVar\(^4\) database. The novel alterations were established according to the American College of Medical Genetics and Genomics (ACMG) guidelines (Richards et al., 2015).

The results were analyzed with in silico prediction software Polyphen2 (Adzhubei et al., 2010) (Polymorphism Phenotyping version 2)\(^5\), SIFT ("Sorting Tolerant From Intolerant")\(^6\) (Kumar et al., 2009), and Mutation Taster\(^7\) (Schwarz et al., 2014).

Histological Investigation (Muscle and Nerve Biopsy)

To confirm the diagnosis of PLAN, the IV/2 proband had muscle and sural nerve biopsy to confirm the presence of PLAN pathological hallmarks. Fresh frozen sections using the routine histochemical staining and araldite embedded ultrathin sections were prepared for light end electron microscopic examinations.

Case Report

Here, we are reporting a Hungarian family with three affected girls out of five children. This is a retrospective case study with institutional ethical committee approval. Informed consent for diagnostic genetic testing was obtained from each individual.

Family History

The mother of the proband (III/4) and two of her sisters (III/6 and III/7) were treated with depression. The maternal grandmother had a history of a benign renal tumor and cardiovascular diseases

Keywords: neurodegeneration with brain iron accumulation II (NBIA2B), PLA2G6 gene, PLA2G6-associated neurodegeneration (PLAN), neuroaxonal dystrophy, Dystonia-Parkinsonism syndrome
Toth-Bencsik et al. New Insights of PLAN Phenotype

(II/4), in addition to the death of two of her siblings during early childhood due to unidentified causes. One of the aunts and uncle committed suicide (II/7 and II/8), another aunt had suicidal tendencies (II/13), while an uncle had late onset Parkinsonian syndrome (II/9). The healthy sister of the mother has four children, three daughters of which developed transient muscle hypotonia before the age of 2 years (IV/8, IV/9, and IV/10). Her son is healthy (IV/7). The father of the patient had hypoacusis and impulse control disorder (III/3), his father (I/1) and grandfather (II/1) were alcoholics (Figure 1).

RESULTS

Patients’ History (Figure 2)

Patient IV/2 and IV/3 (24-Years Old)

Patient IV/2 and IV/3 were born as identical twins at the 38th gestational week with Apgar 10/10, followed by a few days of neonatal jaundice. They started to speak fluently at age of 2.5. The first symptoms presented at age of 3 in both children. The earliest signs were gait instability and speech deterioration, followed by the development of severe spastic paraparesis with moderate ataxia within a few years. At age of 14, IV/2 had mild dyskinesia and severe dystonia in the limbs. She became wheelchair-bound. At age 20 she had severe impulse control problems. At age 21, the dyskinesia progressed in the upper limbs, choreiform movements appeared and she became bradykinetic, the dysphagia and the ability to speak worsened and she had a generalized epileptic seizure. From age 22, she had episodic agitation, anxiety and acoustic hallucinations which were controlled by low dose quetiapine. One year later she lost her initiative and was characterized by amotivation, alogia, and apathy. The dysphagia, rigidity and bradykinesia were progressed.

Neurological examination of patient IV/2 (at age 16) revealed macrocephaly, micrognathia, prominent forehead, bilateral ptosis, vertical gaze palsy, severe dysarthria, mild dysphagia, severe spastic tetraparesis in all limbs truncal and limb ataxia, upper limb dysdiadochokinesis, dystonia in the feet, hyperactive tendon reflexes with bilateral pyramidal signs, urinary retention and obstration. She was able to stand with bilateral support. She developed severe cognitive decline and emotional lability during her follow-up. At age 21, she developed severe dyskinesia in both arms. Her speech regressed. She was able to communicate only with a few words.

Routine laboratory results, acylcarnitine profile, ceruloplasmin, ferritin, organic and amino acid levels were normal. Her EEG (electroencephalogram) detected bilateral synchronic theta bursts and irritative signs in the frontal regions. ENG (electronystagmography) revealed axonal neuropathy. EMG (electromyography) was normal at age 10 years. BAEP (brainstem auditory evoked potential) detected bilaterally increased wave V latency. VEP (Visual Evoked Potential) detected bilateral prolonged P100 latency. The abdominal ultrasound was normal.

Patient IV/3 was 3-years old at the time of developing the first psychiatric symptoms (irritability and emotional lability) and the first epileptic seizure. A few years later she developed urinary retention and constipation. The disease progressed, her speech deteriorated quickly and severe somatomental regression was present at the age of 10. She became wheelchair-bound at age of 14. Her mood was stable. She did not have chorea, but dystonia has been observed in the feet. Although her spastic paraparesis and ataxia progressed, she is able to walk a few steps with aid at the age of 22. She has obsessive-compulsive symptoms.

Neurological examination of patient IV/3 at age 16 detected micrognathia, synophrys, bilateral optic nerve atrophy (without retinal hyperpigmentation), supranuclear vertical gaze palsy, hypomimia, mild dysarthria, hypophonia, dysphagia. Rigidity was observed in the arms, spasticity in the legs. She had proximal tetraparesis, severe truncal and limb ataxia, dysdiadochokinesis in the upper limbs, hyperactive tendon reflexes with bilateral pyramidal signs and urinary incontinence. She was able to walk with aid. Mental regression, obsessive compulsive behavior and

FIGURE 1 | Pedigree of the affected family. The pedigree of the investigated family is presented with some clinical data from the family history and the results of the identified two PLA2G6 gene mutations.
anxiety were detected. At age 18, she developed dystonia in the feet. Her disease progressed very slowly. At age 22, she is still able to walk with bilateral support. Her speech did not deteriorate.

She had slightly increased serum cholesterol and decreased triglycerides. Other laboratory test results were within the normal range. Because of the supranuclear vertical gaze palsy and psychiatric signs associating with movement disorder bone marrow aspiration was performed, in which sea blue histiocytes were present. EEG showed intermittent generalized slow and fast paroxysms EMG, ENG, and BAEP were normal at age 10 years. VEP detected bilateral prolonged P100 latency at age 16.

**Patient IV/4 (22-Years Old)**

She was born at week 40 with Apgar 10/10. She had normal postnatal somatomental development, started to walk at the age of 10 months and talked at 14 months. The first signs presented at the age of 2 with gait instability. Progressive spastic paraparesis developed with ataxic gait. She had parathyroidectomy and subtotal thyroidectomy due to a parathyroid adenoma at the age of 14. At age 15, she was not able to stand up alone or to walk without support; at age 20 she became wheelchair-bound. At age 14, she was episodically aggressive and an obsessive behavior started, which worsened at age 18, at the time of which she became autoaggressive.

Neurological examination of the patient at age 14 revealed vertical gaze palsy, hypophonia, and severe spastic tetraparesis with proximal predominance. Both hands and feet were in a dystonic posture. She had truncal and limb ataxia, hyperactive tendon reflexes with pyramidal signs and urinary incontinence. A severe cognitive deficiency was present. At age 18, she developed severe impulse-control disorder with compulsive behavior and autoaggressiveness. At age 20, her spastic paraparesis and ataxia progressed.

She had increased serum cholesterol and triglyceride. Other routine laboratory results, acylcarnitine profile, organic acid, and amino acid levels were normal. Filipin staining was stronger in her fibroblasts than in the normal control, but the level of oysterol was normal. The abdominal ultrasound detected nephrolithiasis. EMG and ENG were normal at age 8 years, two years later mild axonal lesion was detected. EEG registered diffuse background slowing with bursts of generalized slow wave paroxysms and fast rhythms. BAEP was normal. VEP detected prolonged P100 latency on both side.

**Neuroimaging**

The MRI was followed up from age 10 and 8 years in the sisters. The first MRI detected cerebellar atrophy and mild cerebral atrophy in patient IV/2. In patient IV/3 at age 10 only mild cerebral atrophy was present. Patient IV/4 had mild periventricular T2 hyperintensity. The brain iron accumulation was identified 6 years later in all three children. The last representative brain MRI images of the patients and their parents are shown in Figure 3, and the detected abnormalities are summarized in Table 1. All three affected children demonstrated brain iron accumulation in the globi pallidi internus (Gpi), and substantiae nigrae, while this was absent in the parents. Cerebellar atrophy and the so-called apparent claval hypertrophy was a consistent feature in all three affected children, and patient IV/4 presented the characteristic sign of vertically oriented splenium of the corpus callosum, as well as white matter lesions. The parents also showed mild MRI abnormalities without brain iron accumulation, which may be related to the PLA2G6 carrier state. The father had mild cerebellar atrophy and the thinning of the isthmus of the corpus callosum and enlarged vascular spaces. In the mother, the apparent claval hypertrophy sign was
FIGURE 3 | Representative MRI imaging pictures of the family. Every line represents images from a single individual. (A) IV/2; (B) IV/3; (C) IV/4; (D) III/3; and (E) III/4

Column 1–2. Axial iron sensitive sequences (SWI in line A, and T2* in the remaining) through the basal ganglia and midbrain. Column 3: Sagittal midline T1 images. Findings are summarized in the associated table. Every patient diagnosed with PLAN (A–C) showed iron accumulation in the globi pallidi internus and substantiae nigrae, while the carrier parents did not show iron accumulation. Cerebellar atrophy was present in all the three affected children [(A–C), yellow arrows], and was also present at the father [(D/3), yellow arrow]. The characteristic vertical splenium corpus callosum was present at patient IV/4 [(C/3), yellow star], however, also at the father corpus callosum was atypical [markedly thin isthmus in an adult; (D/3) yellow star]. The apparent claval hypertrophy sign was present at all three affected children [(A–C), red arrow], and was identifiable at also the carrier mother [(E/3), red arrow]. Besides, patient IV/4 also had white matter lesions identifiable on T2 images [(C/4), dotted arrows]. At the father enlarged vascular spaces were detected (D/4). In summary, it seems, that besides the characteristic PLAN-associated signs at the affected children, both parents showed mild abnormalities, which might be related to the PLA2G6 carrier state, without pathological iron accumulation.
TABLE 1 | The results of the brain MRI.

| Iron Gpi | Iron SN | Cerebellar atrophy | Cerebellar high signal | Hypoplastic optic chiasm | Vertical splenium | White matter lesions | Hypertrophy of the clava |
|----------|---------|--------------------|------------------------|--------------------------|------------------|---------------------|------------------------|
| VI/2     | Yes     | Yes                | Yes                    | No                       | No               | No                  | Yes                    |
| VI/3     | Yes     | Yes                | Yes                    | No                       | No               | No                  | Yes                    |
| VI/4     | Yes     | Yes                | No                     | No                       | Yes              | Yes                 | Yes                    |
| III/3    | No      | No                 | Mild                   | No                       | No               | No (isthmus)        | No                     |
| III/4    | No      | No                 | No                     | No                       | No               | No                  | Yes                    |

The identified morphological alterations detected by the brain MRI in the patients and their parents.

present. Patient IV/2 had a DaTscan which displayed normal levels in the right basal ganglia and decreased DaT uptake on the left side.

Histological Investigation (Muscle and Nerve)
In the muscle biopsy of patient IV/2 dominantly scattered rounded atrophic muscle fibers and rarely occurring angular atrophic fibers were observed. EM detected accumulation of lipid vacuoles and glycogen with slight mitochondrial proliferation in the subsarcolemmal and intermyofibrillar area. At age 16 the number of axons in the sural nerve was reduced by 30%, with the presence of small regenerating axon clusters. Some of these axons had a thinned myelin sheath. Electron microscopy detected decompaction of myelin, tubulovesicular structures in the spheroids, and enlarged, abnormal mitochondria (Figures 4A–D).
TABLE 2 | The phenotypic overlap of the patients with the allelic disorders associated with PLA2G6.

| INAD | ANAD | DP | Overlap | ID | IC | Term/Entity Name | IV/2 | IV/3 | IV/4 |
|------|------|----|---------|----|----|------------------|------|------|------|
| Yes  | Yes  | Yes | 3       | HP:0012675 | Infinity (4) | Iron accumulation in brain | +    | +    | +    |
| Yes  | 1    |     |         | HP:0025163 | Infinity (4) | Abnormality of optic chiasm morphology | –    | –    | –    |
| Yes  | 1    |     |         | HP:0031833 | Infinity (4) | Hypometric upward saccades | +    | +    | +    |
| Yes  | 1    |     |         | HP:0006892 | 3.56 | Frontotemporal cerebral atrophy | –    | –    | –    |
| Yes  | 1    |     |         | HP:0030890 | 3.56 | Hyperintensity of cerebral white matter on MRI | –    | –    | –    |
| Yes  | 1    |     |         | HP:0006568 | 3.26 | Eyelid apraxia | –    | –    | –    |
| Yes  | 1    |     |         | HP:0003444 | 3.09 | EMG: chronic denervation signs | –    | –    | –    |
| Yes  | 1    |     |         | HP:0000338 | 3.02 | Hypomimic face | –    | +    | –    |
| Yes  | 1    |     |         | HP:0001884 | 2.96 | Talipes calcaneovalgus | –    | –    | –    |
| Yes  | 1    |     |         | HP:0002510 | 2.82 | L-dopa responsive Parkinsonism | –    | –    | –    |
| Yes  | 1    |     |         | HP:0100710 | 2.75 | Impulsivity | +    | –    | +    |
| Yes  | 1    |     |         | HP:0002145 | 2.72 | Frontotemporal dementia | +    | –    | +    |
| Yes  | 1    |     |         | HP:0006605 | 2.63 | Supranuclear gaze palsy | +    | –    | +    |
| Yes  | 1    |     |         | HP:0002312 | 2.61 | Clumsiness | +    | –    | +    |
| Yes  | 1    |     |         | HP:0002172 | 2.52 | Postural instability | +    | –    | +    |
| Yes  | 2    |     |         | HP:000751 | 2.50 | Personality changes | +    | –    | +    |
| Yes  | 1    |     |         | HP:0007772 | 2.43 | Impaired smooth pursuit | +    | –    | +    |
| Yes  | 1    |     |         | HP:000712 | 2.40 | Emotional lability | +    | –    | +    |
| Yes  | 1    |     |         | HP:0002075 | 2.36 | Dysdiadochokinesis | +    | –    | +    |
| Yes  | 1    |     |         | HP:0100660 | 2.36 | Dyskinesia | +    | –    | –    |
| Yes  | 1    |     |         | HP:0003919 | 2.35 | Death in childhood | –    | –    | –    |
| Yes  | 1    |     |         | HP:0003324 | 2.31 | Generalized muscle weakness | +    | –    | –    |
| Yes  | 1    |     |         | HP:0003678 | 2.27 | Rapidly progressive | –    | –    | –    |
| Yes  | 1    |     |         | HP:0005070 | 2.24 | Abnormal saccadic eye movements | +    | –    | –    |
| Yes  | 1    |     |         | HP:000735 | 2.24 | Impaired social interactions | +    | –    | –    |
| Yes  | 1    |     |         | HP:0002080 | 2.24 | Intention tremor | +    | –    | –    |
| Yes  | 1    |     |         | HP:0002317 | 2.20 | Unsteady gait | +    | –    | –    |
| Yes  | 2    |     |         | HP:0002067 | 2.17 | Bradykinesia | +    | –    | –    |
| Yes  | 1    |     |         | HP:0009027 | 2.14 | Foot dorsiflexor weakness | +    | –    | –    |
| Yes  | 1    |     |         | HP:000736 | 2.12 | Short attention span | +    | –    | –    |
| Yes  | 1    |     |         | HP:0002510 | 2.10 | Spastic tetraplegia | +    | –    | –    |
| Yes  | 1    |     |         | HP:0002375 | 2.06 | Developmental regression | +    | –    | –    |
| Yes  | 1    |     |         | HP:0002270 | 2.02 | Abnormality of the autonomic nervous system | +    | –    | –    |
| Yes  | 1    |     |         | HP:0011463 | 2.01 | Childhood onset | +    | –    | –    |
| Yes  | 1    |     |         | HP:0001300 | 1.99 | Parkinsonism | -    | +    | –    |
| Yes  | 1    |     |         | HP:0000716 | 1.98 | Depressivity | +    | –    | –    |
| Yes  | 1    |     |         | HP:001310 | 1.97 | Dysmetria | –    | +    | –    |
| Yes  | 1    |     |         | HP:0002063 | 1.96 | Rigidity | –    | +    | –    |
| Yes  | 1    |     |         | HP:0000762 | 1.95 | Decreased nerve conduction velocity | –    | –    | –    |
| Yes  | 1    |     |         | HP:0002066 | 1.89 | Gait ataxia | +    | –    | –    |
| Yes  | 1    |     |         | HP:0002072 | 1.85 | Chorea | +    | –    | –    |
| Yes  | 1    |     |         | HP:0000718 | 1.84 | Aggressive behavior | +    | –    | –    |
| Yes  | 1    |     |         | HP:0000729 | 1.79 | Autistic behavior | –    | –    | –    |
| Yes  | 1    |     |         | HP:0002353 | 1.73 | EEG abnormality | +    | –    | –    |
| Yes  | 2    |     |         | HP:0002071 | 1.72 | Abnormality of extrapyramidal motor function | +    | –    | –    |
| Yes  | 1    |     |         | HP:0003487 | 1.61 | Babinski sign | +    | –    | –    |

(Continued)
| INAD | ANAD | DP | Overlap | ID | IC | Term/Entity Name | IV/2 | IV/3 | IV/4 |
|------|------|----|---------|----|----|------------------|------|------|------|
| Yes  | 1    | HP:0002015 | 1.60 | Dysphagia | +   | + | − |
| Yes  | 1    | HP:0001284 | 1.57 | Areflexia | −   | − | − |
| Yes  | Yes | 2    | HP:0001286 | 1.57 | Mental deterioration | + | + | + |
| Yes  | Yes | 2    | HP:0001272 | 1.54 | Cerebellar atrophy | + | + | + |
| Yes  | 1    | HP:0003236 | 1.54 | Elevated serum creatine kinase | − | − | − |
| Yes  | Yes | 2    | HP:0001322 | 1.53 | Dystonia | + | + | − |
| Yes  | 1    | HP:0007256 | 1.51 | Abnormal pyramidal sign | + | + | + |
| Yes  | 1    | HP:0000648 | 1.50 | Optic atrophy | − | − | − |
| Yes  | 1    | HP:0003676 | 1.50 | Progressive | + | + | + |
| Yes  | Yes | 2    | HP:0001337 | 1.49 | Tremor | − | + | − |
| Yes  | Yes | 3    | HP:0002059 | 1.45 | Cerebral atrophy | + | + | + |
| Yes  | 1    | HP:000750 | 1.38 | Delayed speech and language development | − | − | − |
| Yes  | Yes | 2    | HP:0001260 | 1.36 | Dysarthria | + | + | + |
| Yes  | 1    | HP:0011968 | 1.35 | Feeding difficulties | + | + | − |
| Yes  | Yes | 2    | HP:0001347 | 1.34 | Hyperreflexia | + | + | + |
| Yes  | 1    | HP:0003593 | 1.28 | Infantile onset | − | − | − |
| Yes  | 1    | HP:0001327 | 1.18 | Spasticity | + | + | + |
| Yes  | 1    | HP:0000639 | 1.17 | Nystagmus | − | − | − |
| Yes  | Yes | 2    | HP:0001288 | 1.16 | Gait disturbance | + | + | + |
| Yes  | Yes | 2    | HP:0001251 | 1.15 | Ataxia | + | + | + |
| Yes  | 1    | HP:0001278 | 1.12 | Hypertonia | + | + | + |
| Yes  | 1    | HP:0001252 | 0.88 | Muscular hypotonia | − | − | − |
| Yes  | Yes | 2    | HP:0001250 | 0.83 | Seizure | + | − | − |
| Yes  | 1    | HP:0012758 | 0.75 | Neurodevelopmental delay | − | − | − |
| Yes  | 1    | HP:0100022 | 0.75 | Abnormality of movement | + | + | + |
| Yes  | 1    | HP:0001249 | 0.72 | Intellectual disability | + | + | + |
| Yes  | 1    | HP:0011804 | 0.63 | Abnormal muscle physiology | + | + | + |

**Additional features:**
- Postnatal icterus
- Macrocephalia
- Prominent forehead
- Prominent forehead
- Micrognathia
- Prominent forehead
- Muscle biopsy:
  - Micrognathia
- Myopathic changes (round fibers)
- Nerve biopsy:
  - Relative slower progression
- Axonal-demyelinating neuropathy

The table shows the phenotypic overlap of the three affected individual with the allelic disorders associated with PLA2G6 gene. Phenotypic features were extracted from the OMIM clinical synopsis table, then mapped to their corresponding human phenotype ontology (HPO) term, and sorted according to their specificity (i.e., information content = IC). In the first three column we “yes” designates, that the HPO-term in the given row is associated with the allelic disorder in the OMIM. In the last three column “+” or “−” designates whether the given phenotypic abnormality is present in the given family member or not. Scores for the allelic disorders (INAD, ANAD, and DP) were calculated for the patients as following: if the given patient showed a symptom, which is present in a given allelic disorder, then she received a score for that allelic disorder equal to the information content of that phenotypic abnormality. All the phenotypic abnormality were then summed for every patient and every allelic disorder. Additional features of the patients, which are not described in OMIM, but are considered important are listed for every patient.
**Genetic Investigations**

In the PLA2G6 gene a novel p.P622S (c.1864C > T) and a known pathogenic p.R600W (c.1798 C > T) rare variants were present in all siblings. The novel p.P622S variant (prediction scores: GERP: 4.43, Mutation Taster: 0.9875 – disease causing, Polyphen-2_HVAR (0.297), SIFT: 0.453 – tolerated) was classified as variant of uncertain significance according to ACMG guideline (PM1, PM2, PP2, and BP4) (Richards et al., 2015). Segregation analysis detected the heterozygous p.P622S mutation in the father of the proband, while, the heterozygous R600W mutations was identified in the mothers. One of their healthy siblings inherited the PLA2G6 genotype of the mother, the other the genotype of the father. The aunt III/6 harbored the R600W mutation too. The sequence of the NPC1 (NM_000271.5), PANK2 (NM_153638.3), MPAN (NM_031448.6), and CP (NM_000096.4) genes were normal. Large deletions and/or duplications of the PLA2G6/PANK2 gene were excluded by Multiplex Ligation-Dependent Probe Amplification (SALSA MLPA probe mix P120B2; MRC Holland, Amsterdam, Netherlands).

**DISCUSSION**

Here, we report a long-term follow-up study of a Caucasian family with three affected children harboring one novel and one known pathogenic mutations of PLA2G6 gene leading to a colorful clinical picture. Several authors have highlighted the heterogeneity of the clinical and radiological presentation in PLAN associated disorders (Nardocci et al., 1999; Gregory et al., 2008, 2009; Karkheiran et al., 2015). The studied family further demonstrates that the disease is indeed a spectrum rather than discrete entities. The disease onset and the most prominent features, such as eye movement disturbances, ataxia, dystonia, psychomotor regression, and cerebellar atrophy with iron accumulation and the relatively slow progression best resemble ANAD (Table 2), however, some features are more closely related to INAD or Dytsotonia-Parkinsonism. For example the severe tetraparesis and the detected MRI changes (prominent cerebellar atrophy with the apparent claval hypertrophy and corpus callosum alterations) are more characteristic of INAD. The optic nerve atrophy observed in one twin also supports this notion (Gregory et al., 2008). The finding of MRI hyperintensity in both the globus pallidus and substantia nigra is reported in children having ANAD, whereas it is considered a later neuroradiological marker in INAD. On the other hand, the predominant neuropsychiatric features, Parkinsonism in conjunction with decreased DaT signal are more characteristic of the Dystonia-Parkinsonism phenotype (Gregory et al., 2009). All children had OCD symptoms, displayed most prominently in the youngest girl, who had severe anxiety and autoagression, associated with severe impulsivity. One of the twins also had severe agitation, hallucinations and severe anxiety. None of the studied individuals had depression. While the severe speech deterioration is not reported in the literature, it can be a component of the severe psychomotor regression. We also emphasize the prominent expression of minor abnormalities (macrocephaly, micrognathia, prominent forehead, and synophrys) in all affected members of the family, which are not frequently mentioned in the literature.

In PLAN, the neuroradiological features are changing dynamically. The first sign in the siblings in our study was cerebellar atrophy without brain iron accumulation. This is in accordance with the observation of Darling et al. who concluded that cerebellar atrophy is a universal radiological sign in infantile and childhood onset PLAN and it is correlated with the severity of the phenotype. The presence of the iron accumulation within the globi pallidi and substantiae nigrae is also a common uniform feature regardless of the phenotype (Nardocci et al., 1999; Darling et al., 2019), however, iron deposition was not detected on initial neuroimaging in many of the infantile cases (Il1ingworth et al., 2014).

Upon consideration of the longitudinal history of our cases and the literature data, we can conclude that the clinical picture, the neuroradiological and electrophysiological parameters changed dynamically with the disease progression. Historically, the classification of the disease subgroups was based primarily on the age at onset and selected biomarkers. At this is not always feasible, use of the term PLAN spectrum disease is more appropriate (Ozes et al., 2017). Recently the spectrum was further expanded with complicated hereditary spastic paraparesis (Koh et al., 2019) and pure Parkinsonism without iron accumulation also (Chu et al., 2020). Intrafamilial discordant clinical phenotype such as spastic paraplegia and dopa responsive Parkinsonism with claval hypertrophy ad without brain iron accumulation was reported by Park et al. (2019). In this family, the patients had homozygous R747W mutations in PLA2G6. Here we report a new intrafamilial clinical discordancy in association with compound heterozygous PLA2G6 mutations (p.R600W, p.P622S). Both of these missense variants are located in a mutational hot spot region found, in a critical and well-established functional PNPLA domain, which can explain the loss of function of the PLA2G6 protein. The p.R600W is a new disease causing mutation. Another amino acid change at the same position in the PLA2G6 gene (R600Q) has previously been reported in a homozygous state in a patient with INAD (Paisan-Ruiz et al., 2012).

The family had a long diagnostic journey since the vertical gaze palsy, the sea-blue histiocytes, and the positive filipin staining misled the clinical diagnostic. Since NPC1 and hematological disorders were excluded, sea blue histiocytes could be explained by enhanced creation of ceroid lipofuscin concentrating in macrophages. This can occur in NBIA as well, which is consistent with the consensus that defective lipid metabolism is present in various types of NBIA (Aoun and Tiranti, 2015; Colombelli et al., 2015). In vitro study of the PLA2G6 knockouts detected neuropathological alterations similar to the ones described in our cases (Beck et al., 2011).

The family history of the siblings is also very colorful. Several symptoms potentially associated with PLAN are present from both paternal and maternal sides. Karkheiran et al. (2015) and Guo et al. (2018), respectively, have reported depression and Parkinsonism as a presenting symptom in several families. In this family both symptoms occurred frequently. Unfortunately, the segregation studies could not be performed in all relatives.
Other authors have suggested that heterozygous PLA2G6 variants might be a risk factor for sporadic Parkinson’s disease (Gui et al., 2013; Daida et al., 2021). Daida et al. (2021) reported that the variants of PLA2G6 may be associated with both familial and early onset sporadic Parkinson’s disease either as a monogenic cause (harboring homozygous or compound heterozygous mutations) or as a genetic risk factor (harboring heterozygous mutation). In the family described by us, the parents until age of 57 did not show signs of Parkinsonism; however, the MRI detected mild abnormalities which might be in association with PLA2G6 variants. One maternal uncle had late onset PD. Our hypothesis is that the presence of the heterozygous pathogenic variants are not completely silent clinically, however, this must be studied systematically in a larger number of families.

In conclusion: the colorful clinical symptoms, the slightly discordant clinical picture in the identical twins and the neuroimaging data in the family support the view that despite the distinct age-related phenotypes defined in PLAN, strict disease categories cannot be established, rather, a continuous phenotypic spectrum with variable age at onset should be considered. The phenotype is not always in accordance with the classical disease subgroups, especially when findings are based solely on cross-sectional clinical data. The mild MRI alterations of the asymptomatic parents and the family history suggest that heterozygous pathogenic variants might be associated with clinical symptoms, although systematic study of heterozygous family members is warranted.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

REFERENCES

Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., et al. (2010). A method and server for predicting damaging missense mutations. Nat. Methods, 7, 248–249. doi: 10.1038/nmeth0410-248
Aoun, M., and Tiranti, V. (2015). Mitochondria: a crossroads for lipid metabolism defect in neurodegeneration with brain iron accumulation diseases. Int. J. Biochem. Cell Biol. 63, 25–31. doi: 10.1016/j.biocel.2015.01.018
Beck, G., Sugiuira, Y., Shizawa, K., Kato, S., Setou, M., Tsujimoto, Y., et al. (2011). Neuroaxonal dystrophy in calcium-independent phospholipase A2beta deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. J. Neurosci. 31, 11411–11420. doi: 10.1523/NEUROSCI.0345-11.2011
Carrillo, J., Santos, M., Guimarães, A., Teixeira, J., Chorão, R., Martins, M., et al. (2008). Infantile neuroaxonal dystrophy: what’s most important for the diagnosis? Eur. J. Paediatr. Neurol. 12, 491–500. doi: 10.1016/j.epjpn.2008.01.005
Chu, Y. T., Lin, H. Y., Chen, P. L., and Lin, C. H. (2020). Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review. BMC Neurol. 20:101. doi: 10.1186/s12883-020-01686-4
Colombelli, C., Aoun, M., and Tiranti, V. (2015). Defective lipid metabolism in neurodegeneration with brain iron accumulation (NBIA) syndromes: not only a matter of iron. J. Inherit. Metab. Dis. 38, 123–136. doi: 10.1007/s10545-014-9770-2

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Hungarian Research Ethics Committee. Approval number was: 44599–2/2013/EKU (535/2013.) The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RT-B and MM designed and conducted the study, PB, EV, AL, and MM investigated the patients and their family members, and analyzed the clinical data. GR performed the MRI studies. RT-B, PB, and MM wrote the manuscript. All authors read and approved the final version of the manuscript.

FUNDING

This study was supported by the Research and Technology Innovation Fund by the Hungarian National Brain Research Program (KTIA_NAP_2017-1.2.1-NKP-2017-00002) and the FIKP2020.

ACKNOWLEDGMENTS

The authors thank to the patients and family members for their participation in the study, Mariann Markó for the histological assistance. The Institute of Genomic Medicine and Rare Disorders is the member of the European Reference Network for Rare Neurological Disorders.

Daida, K., Nishioka, K., Li, Y., Yoshino, H., Shimada, T., Dougu, N., et al. (2021). PLA2G6 variants associated with the number of affected alleles in Parkinson’s disease in Japan. Neurobiol. Aging 97, 147.e1–147.e9.
Darling, A., Aguiler-Albasa, S., Tello, C. A., Serrano, M., Tomás, M., Camino-León, R., et al. (2019). PLA2G6-associated neurodegeneration: new insights into brain abnormalities and disease progression. Parkinsonism Relat. Disord. 61, 179–186. doi: 10.1016/j.parkreldis.2018.10.013
Gregory, A., Polster, B. J., and Hayflick, S. J. (2009). Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J. Med. Genet. 46, 73–80. doi: 10.1136/jmg.2008.061929
Gregory, A., Westaway, S. K., Holm, I. E., Kotzbauer, P. T., Hogarth, P., Sonék, S., et al. (2008). Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 71, 1402–1409. doi: 10.1212/01.wnl.0000327094.67726.28
Gui, Y. X., Xu, Z. P., Wen, L. V., Liu, H. M., Zhao, J. J., and Hu, X. Y. (2013). Four novel rare mutations of PLA2G6 in Chinese population with Parkinson’s disease. Parkinsonism Relat. Disord. 19, 21–26. doi: 10.1016/j.parkreldis.2012.07.016
Guo, Y. P., Tang, B. S., and Guo, J. F. (2018). PLA2G6-associated neurodegeneration (PLAN): review of clinical phenotypes and genotypes. Front Neurol 9:1100. doi: 10.3389/fneur.2018.01100
Illingworth, M. A., Meyer, E., Chong, W. K., Manzur, A. Y., Carr, L. J., Younis, R., et al. (2014). PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with
infantile and atypical childhood-onset disease. *Mol. Genet. Metab.* 112, 183–189. doi: 10.1016/j.ymgme.2014.03.008

Ji, Y., Li, Y., Shi, C., Gao, Y., Yang, J., Liang, D., et al. (2019). Identification of a novel mutation in PLA2G6 gene and phenotypic heterogeneity analysis of PLA2G6-related neurodegeneration. *Parkinsonism Relat. Disord.* 65, 159–164. doi: 10.1016/j.parkreldis.2019.04.002

Karkheiran, S., Shahidi, G. A., Walker, R. H., and Paisán-Ruiz, C. (2015). PLA2G6-associated dystonia-parkinsonism: case report and literature review. *Tremor. Other Hyperkinet. Mov. (N. Y.)* 5:317. doi: 10.5334/tohm.254

Koh, K., Ichinose, Y., Ishiura, H., Nan, H., Mitsui, J., Takahashi, J., et al. (2019). PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia. *J. Hum. Genet.* 64, 55–59. doi: 10.1038/s10038-018-0519-7

Kumar, P., Henikoff, S., and Ng, P. C. (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat. Protoc.* 4, 1073–1081. doi: 10.1038/nprot.2009.86

Kurian, M. A., Morgan, N. V., MacPherson, L., Foster, K., Peake, D., Gupta, R., et al. (2008). Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). *Neurology* 70, 1623–1629. doi: 10.1212/01.wnl.0000310986.48286.8e

Nardocci, N., Zorzi, G., Farina, L., Binelli, S., Scialoli, W., Ciano, C., et al. (1999). Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. *Neurology* 52, 1472–1478. doi: 10.1212/wnl.52.7.1472

Ozes, B., Karagoz, N., Schüle, R., Rebeiro, A., Sobrido, M. J., Harmuth, F., et al. (2017). PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia. *Clin. Genet.* 92, 534–539. doi: 10.1111/cge.13008

Paisan-Ruiz, C., Li, A., Schneider, S. A., Holton, J. L., Johnson, R., Kidd, D., et al. (2012). Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. *Neurobiol. Aging* 33, 814–823. doi: 10.1016/j.neurobiolaging.2010.05.009

Park, J., Youn, J., and Cho, J. W. (2019). Intrafamilial variability and clinical heterogeneity in a family with PLA2G6-associated neurodegeneration. *Precis. Future Med.* 3, 135–138.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* 17, 405–424. doi: 10.1038/gim.2015.30

Schwarz, J. M., Cooper, D. N., Schuelke, M., and Seelow, D. (2014). MutationTaster2: mutation prediction for the deep-sequencing age. *Nat. Methods* 11, 361–362. doi: 10.1038/nmeth.2890

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Toth-Bencsik, Balicza, Varga, Lengyel, Rudas, Gal and Molnar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.